Oncology Nursing Brown Bag Lunch

Triple Negative Breast Cancer: Brief Review and Perspectives

Alexandra Zimmer, MD
Assistant Research Physician, Clinical Director
Women’s Malignancies Branch, Center for Cancer Research, NCI

DATE: Wednesday January 22, 2020
TIME: 2:00 PM - 3:00 PM
LOCATION: Room 2-3330

Session Description:

Triple Negative Breast Cancer (TNBC) accounts for 10-20% of all breast cancers and is defined by the absence of estrogen and progesterone receptors along with the absence of HER2 amplification. Patients do not benefit from known targeted therapies to ER or HER2. Standard therapy for metastatic TNBC is single agent chemotherapy but the overall response rate is 30%. A review of breast cancer will be presented along with current and potential future treatments.

This activity has been submitted to the Ohio Nurses Association for approval to award contact hours. The Ohio Nurses Association is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91).